Theradex Oncology (United States)

Recent papers from Theradex Oncology (United States)

1. Comparing the effects of commercial to open initial specimen diversion techniques on clinical outcomes and institutional costsInfection Control and Hospital Epidemiology · 2026
2. Reducing Release Failures by 35%: A Case Study on Jira-Jenkins-Azure DevOps IntegrationJournal of Information Systems Engineering & Management · 2025
3. Abstract CT196: First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumorsCancer Research · 2024
4. Abstract CT201: Phase 2 clinical trial of OKN-007 in recurrent malignant gliomaCancer Research · 2024
5. Abstract CT040: First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancerCancer Research · 2024
6. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumorsInvestigational New Drugs · 2020
7. Loss of consciousness and altered mental state predicting depressive and post-concussive symptoms after mild traumatic brain injuryBrain Injury · 2019
8. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical TrialsJournal of Clinical Oncology · 2016
9. Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent TrialsJNCI Journal of the National Cancer Institute · 2012
10. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumoursBritish Journal of Cancer · 2011
11. A phase II study of irinotecan (CPT‐11) in patients with advanced squamous cell carcinoma of the cervixCancer · 1998
12. Reversal of Tumor-Induced Immunosuppression: A New Approach to Cancer TherapyJournal of Immunotherapy · 1997